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➣  Medicine is confronting an inforMation explosion, 
an incredibly “rapid increase in the amount of informa-
tion available.”1 Although this vast wealth of knowledge 
has indisputably benefited medical care, it can be diffi-
cult to stay abreast of the large volume of information 
published in both the peer-reviewed and grey literature. 
Practical strategies to organize the swelling tide of med-
ical literature are essential for providers to recognize 
and incorporate new information into practice.  
One strategy for managing new information is the 
traditional annual review, in which selected, appraised 
articles are presented for general consumption.2,3 Here, 
we present five notable articles for general internal medi-
cine published from 1 Sept. 2010 to 31 Aug. 2011, with 
focused summaries of their key findings and supporting 
clinical vignettes to highlight their significance. 
Methods
A hand-search was performed (by CvW) of all manu-
script titles and abstracts for primary studies published 
between 1 Sept. 2010 to 31 Aug. 2011 in the New England 
Journal of Medicine, the Journal of the American Med-
ical Association, the Annals of Internal Medicine, the 
Archives of Internal Medicine, the Canadian Medical 
Association Journal, the British Medical Journal, and 
The Lancet. These seven highly cited general medical 
journals were chosen on the basis of their broad reader-
ship, general visibility, and established reputation for 
publishing important and high-quality articles. After a 
preliminary screen, 42 studies were identified as having 
very significant potential for influencing current practice 
or policy. Of these, five notable articles were selected on 
the basis of a combination of factors, including the qual-
ity of the study, the prevalence of the medical issue ad-
dressed by the study, and the study’s possible impact on 
current treatment paradigms, diagnostic strategies, or 
health care policy. Similar criteria have previously been 
proposed to rate the importance of articles.4 It should be 
noted that our literature search was conducted by means 
of a single-person review and that the final selection of 
articles was based on subjective criteria.
1 
Renal ultrasonography for patients with acute 
kidney injury
Clinical vignette. A 52-year old white woman is admit-
ted to hospital with a 5-day history of nausea, vomiting, 
and diarrhea. Her past medical history is unremarkable, 
and she takes no medications. Physical examination is 
consistent with hypovolemia. Investigations reveal an 
elevated serum creatinine of 179 μmol/L (with a baseline 
of 70 μmol/L) and a bland urinalysis. The admitting hos-
pitalist inquires whether renal ultrasonography (RUS) 
should be ordered for further investigation of acute kid-
ney injury (AKI).
Summary of findings. Licurse and colleagues designed 
and validated a clinical prediction rule to identify, among 
patients admitted to hospital with AKI, those who are at 
low risk of hydronephrosis.5 This cross-sectional study 
was conducted at the Yale–New Haven Hospital,from 
January 2005 to May 2009. A total of 997 patients were 
assembled by searching through the local imaging data-
base for RUS studies performed on adult inpatients 
with AKI. Patients were excluded if they were pregnant, 
had a history of renal transplant, or had a diagnosis of 
Licurse A, Kim MC, Dziura J, Forman HP, Formica RN, Makarov DV, 
et al. Renal ultrasonography in the evaluation of acute kidney 
injury: developing a risk stratification framework. Arch Intern Med 
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hydronephrosis in the preceding 30 days. Data from 
the 200 derivation subjects (a sample consisting of 100 
patients with hydronephrosis and another 100 patients 
without this condition) were used to fit a multivariable 
prediction model. Seven independent risk factors asso-
ciated with hydronephrosis were identified; these were 
assigned scores that were tallied to estimate an individ-
ual’s risk for hydronephrosis (see Table 1). Three distinct 
risk groups for hydronephrosis were defined: low risk 
(< 2 points, 1%–20% prevalence), medium risk (3 points, 
20%–40% prevalence), and high risk (> 3 points, > 40% 
prevalence).  
The prediction rule was then applied to 797 subjects 
from the validation cohort. Classifying patients as low-
risk vs mid- and high-risk, the prediction model had a 
sensitivity of 91.8% (95% confidence interval [CI] 89.9%–
93.7%), a specificity of 30.3% (95% CI 27.2%– 33.5%), and 
a negative likelihood ratio of 0.27 for hydronephrosis. For 
the outcome of hydronephrosis requiring intervention 
(i.e., placement of a urologic stent or nephrostomy tube), 
the sensitivity increased to 96.3% (95% CI 94.9%–97.6%), 
with a specificity of 28.8% (95% CI 25.7%–32.0%), and a 
negative likelihood ratio of 0.13. Incidental findings on 
RUS unrelated to hydronephrosis were rare, and none of 
these were found in low-risk patients.
This study received no industry funding.
 
Implication  and  perspectives.  Although RUS is safe, 
noninvasive, and widely available, the indiscriminate 
use of this test may not necessarily be cost-effective or 
beneficial. The results of this study help rationalize the 
diagnostic workup for AKI by identifying patients at low 
risk of obstruction, therefore conserving some resources 
without compromising patient care. Although the study 
population was limited to patients undergoing RUS (a 
sample enriched with cases of obstruction), the resulting 
prediction model would be expected to be even more 
successful at excluding hydronephrosis in unselected 
populations with AKI (among whom the expected preva-
lence of obstruction would be lower).  
Although the results of this carefully designed study 
are useful and readily applied to patient care, two im-
portant issues remain: first, although the model predicts 
hydronephrosis requiring intervention, the investigators 
limited this definition to surgical procedures, thus over-
looking important nonsurgical approaches to obstruction 
(e.g., placement of urinary catheters, discontinuation of 
anticholinergic drugs, etc.); second, although the results 
of this study may guide the initial workup of AKI in 
most patients, clinical judgment should still be used as 
the evaluation of AKI is a complex and nuanced process 
based on clinical factors that cannot be captured fully 
with a simple scoring system alone. 
Resolution  of  clinical  vignette. History, examination, 
and preliminary investigations suggest a pre-renal cause 
for this patient’s AKI. Moreover, the proposed prediction 
rule suggests that she is at low risk for post-renal obstruc-
tion.  As such, the admitting physician and patient decide 
to forgo RUS until other reasonable conservative meas-
ures (e.g., adequate volume expansion) are tried first.
2 
Risk of recurrence after a first seizure
Clinical vignette.  A 32-year-old man is seen in clinic 
for follow-up after his first unprovoked seizure 6 months 
earlier. Investigations, including serum chemistries, 
electroencephalography (EEG), and computed tomog-
raphy of the brain were unremarkable. He has been 
free of seizures since then and has not been on any anti- 
epileptic treatment. He asks when he will be able to safely 
resume driving.
 
Summary  of  findings. Bonnett and colleagues per-
formed a secondary analysis of the Multicentre study of 
early Epilepsy and Single Seizures (MESS), a ran domized 
Table 1 
Clinical prediction rule for hydronephrosis*
Risk factor Points
  History of hydronephrosis † High risk
  Recurrent urinary tract infections 1
  Diagnosis consistent with possible obstruction‡ 1
  Non-black race 1
  Absence of inpatient nephrotoxic medication§ exposure 1
  Absence of congestive heart failure 1
  Absence of pre-renal acute kidney injury¶ 1
* Adapted from Licurse et al. (2010)5 
† History of hydronephrosis (defi  ned as any documented history of hydronephrosis 
or any imaging history of hydronephrosis in the previous 2 years) places patient 
in high-risk category.
‡ Includes benign prostatic hyperplasia, abdominal or pelvic cancer, neurogenic 
bladder, single functional kidney, or previous pelvic surgery.
§ Defi  ned as acetylsalicylic acid (> 81 mg/d), diuretic, angiotensin-converting 
enzyme inhibitor, or intravenous vancomycin
¶ Defi  nition of prerenal acute kidney injury based on history of sepsis or use of 
vasopressors during current hospital admission in the primary model. 
Bonnett LJ, Tudur-Smith C, Williamson PR, Marson AG. Risk of 
recurrence after a first seizure and implications for driving: further 
analysis of the Multicentre study of early Epilepsy and Single Seizures. 
BMJ 2010;341:c6477.  Available from: www.bmj.com/content/341/
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controlled trial conducted from January 1993 to Decem-
ber 2000. MESS determined the effect of early treatment 
with anti-epileptic drugs compared with no (or delayed) 
treatment after an unprovoked seizure.6 This present an-
alysis involved 637 participants aged 16 years and older 
(i.e., of driving age) without previous anti-epileptic treat-
ment or progressive neurological disease. The authors 
sought to identify clinical characteristics independently 
associated with time to recurrent seizure, reporting this 
model as the probability of recurrent seizure over the 
next  year  at  various  times  during  follow-up.  The  final 
multivariable model included the following variables: a 
remote symptomatic etiology (i.e., seizure caused by re-
mote disease or event such as head injury, meningitis, en-
cephalitis, or intracranial disease), history of epilepsy in a 
first-degree relative, seizures only occurring while asleep, 
EEG showing epileptiform activity with focal or general-
ized spikes or spike and slow wave activity, neuro-imaging 
results, and whether the patient initially received anti-
epileptic therapy. Estimates of seizure recurrence risk for 
all possible combination of risk factors from the subgroup 
analyses are published online (see web appendix, avail-
able from www.bmj.com/highwire/filestream/446798/
field_highwire_adjunct_files/0).
This study received no industry funding.
Implication and perspectives. There is a dearth of med-
ical evidence to guide clinicians on the risk of seizure re-
currence after a first unprovoked seizure. Consequently, 
existing guidelines have been informed largely by expert 
opinion and differ widely around the world.7–9 Import-
antly, Bonnett and colleagues address a subject with sub-
stantial knowledge gaps and present findings that have 
considerable implications for public policy. The investi-
gators suggest that the study’s subgroup analyses pro-
vide guidance on individualized risk, and the unadjusted 
results are informative at the population level. 
However, these data should be applied with caution. 
First, this model has not been externally validated. 
Second, relying on the seizure-free interval as the sole 
determinant of driving fitness—one of the most import-
ant utilities of such models—may be misleading, since 
other factors not included in this model (such as the 
presence of auras and previous driving history) have 
been reported as important predictors of seizure-related 
crashes.10 In addition, the seizure-free interval has not 
been shown to be related to seizure-related crashes,11 
or to crash fatalities.12 Therefore, although estimating 
seizure recurrence risk is indisputably important, this 
study is limited by the absence of data on motor vehicle 
collisions (seizure-related or otherwise). Any attempt to 
apply the results of this study to policy should balance 
the issues of public safety with individual factors.
Resolution  of  clinical  vignette. On the basis of the 
study’s findings, this patient is reassured that his risk 
of seizure recurrence in the next 12 months is low. The 
decision regarding when he may resume driving again 
should be determined according to national, prov-
incial, or state regulations. For instance, Canadian 
guidelines recommend that this man should be seen 12 
months after his initial seizure to re-evaluate his abil-
ity to drive, conditional on him remaining seizure-free 
with no further signs of epileptiform activity.9 In con-
trast, the Driving and Vehicle Licensing Agency in the 
United Kingdom suggests that he may resume driving 
now (6 months after his first seizure) because his risk 
of recurrence is less than 20% in the coming year.6,13 
3
Cardiac-resynchronization therapy for mild 
to moderate heart failure
Clinical vignette. A 66-year-old man with heart failure 
resulting  from  ischemic  cardiomyopathy  reports  diffi-
culty climbing two flights of stairs because of shortness 
of breath despite receiving optimal medical therapy.   
An electrocardiogram confirms a sinus rhythm with a 
prolonged QRS duration, and a recent echocardiogram 
revealed an impaired left-ventricular ejection fraction 
(LVEF) of 25%–30%. He is referred to the heart function 
clinic to discuss further treatment options. 
 
Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, et al.  
Cardiac-resynchronization therapy for mild-to-moderate heart failure.  
N Engl J Med 2010;363(25):2385–2395. Available from: www.nejm.org/
doi/full/10.1056/NEJMoa1009540 
 
Summary of findings. The Resynchronization-Defibril-
lation for Ambulatory Heart Failure Trial (RAFT) was a 
multicentre, double-blinded, randomized controlled 
trial that enrolled 1798 patients with NYHA class II or 
III heart failure, a LVEF of ≤ 30%, and a prolonged QRS 
(i.e., intrinsic duration of ≥ 120 msec, or paced duration 
of ≥200 msec).14 In addition to receiving optimal medical 
therapy, participants were randomly assigned to receive 
either  an  implantable  cardioverter-defibrillator  (ICD) 
alone (904 patients) or an ICD with cardiac resynchron-
ization therapy (CRT) (894 patients). After a mean fol-
low-up of 40 months, patients in the ICD-CRT group did 
significantly better with regard to death or hospital ad-
mission for heart failure (hazard ratio [HR] 0.75, 95% CI Clinical practice                                                                                                                          Leung & van Walraven
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0.64–0.87,  p < 0.001), all-cause mortality (ICD-CRT 
28.6%;  ICD  34.6%;  HR  0.75,  95%  CI  0.62–0.91,  p = 
0.003), and hospital admission for heart failure (ICD-
CRT  19.5%;  ICD  26.1%;  HR  0.68,  95%  CI  0.56–0.83, 
p < 0.001).  For  the  primary  outcome,  predefined  sub-
group analyses suggested that ICD-CRT therapy may be 
more  effective  in  patients  with  QRS  durations  ≥ 150 
msec (HR 0.59, 95% CI 0.48 to 0.73, p = 0.003 for inter-
action). Patients receiving combination ICD-CRT were 
more likely to have device-related hospital admissions 
during the course of the study (20.0% vs 12.2%, p < 0.001) 
and device-related complications within the first 30 days 
after implantation (13.3% vs 6.8%, p < 0.001). 
This trial was sponsored by the Canadian Institutes 
of Health Research and Medtronic of Canada. The lat-
ter provided the CRT components but had no role in the 
conduct of the study, the reporting of the data, or the de-
cision to publish the study results.
Implication  and  perspectives.  In recent decades, the 
use of pharmacological therapy and medical devices has 
expanded rapidly to improve the prognosis for patients 
with heart failure.15,16 Until now, however, there has been 
no evidence that CRT confers additional survival bene-
fit when combined with ICD therapy. The results of this 
trial are particularly important, since most patients who 
have NYHA class II or II heart failure, impaired LVEF, 
and widened QRS duration would be suitable candidates 
for  ICD  implantation;17 thus, demonstrating that the 
combination of ICD with CRT improves survival beyond 
ICD alone is potentially transformative to routine care. 
The magnitude of benefit of combination ICD-CRT re-
ported in this rigorously designed study are impressive 
and clinical relevant. Over 5 years, the number needed 
to treat (NNT) to prevent 1 death was 14, and the NNT to 
prevent 1 hospital admission related to heart failure was 
11. Although the results were positive overall, the risks 
of device implantation and its associated complications 
are not inconsequential (with a number needed to harm 
of 16). Accordingly, the decision for device implantation 
should be based on individualized risks and patient pref-
erences after the benefits and risks are weighed.
Resolution of clinical vignette. Although this patient 
already meets established eligibility criteria for ICD 
placement for the primary prevention of sudden cardiac 
death,17 the results of this study further support the use 
of CRT in addition to ICD and optimal medical therapy. 
After the potential risks and expected benefits of im-
plantation are explained to him, the patient consents to 
ICD-CRT therapy and is listed for device implantation.
4 
Apixaban versus warfarin in patients with atrial 
fibrillation
Clinical vignette. An 82-year-old woman is receiving 
warfarin for atrial fibrillation. However, she struggles to 
maintain the international normalized ratio (INR) with-
in the therapeutic range (between 2.0 and 3.0). She finds 
routine monitoring cumbersome and difficult. 
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna 
M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N 
Engl J Med 2011;365(11):981–992.  Available from: www.nejm.org/doi/
full/10.1056/NEJMoa1107039
Summary of findings. The Apixaban for Reduction in 
Stroke and Other Thromboembolic Events in Atrial Fi-
brillation (ARISTOTLE) investigators designed and 
performed a multicentre, double-blinded, random-
ized controlled trial comparing apixaban with warfarin 
(adjusted to an INR of 2.0 to 3.0) for the prevention of 
stroke or systemic embolism in the setting of atrial fibril-
lation.18 Anticoagulation control in the warfarin group 
was excellent, with a median time in therapeutic range of 
66%.  Outcomes analyzed for 18 201 participants from 39 
countries demonstrated that apixaban was superior to 
warfarin in preventing the composite of strokes and sys-
temic embolism (HR 0.79, 95% CI 0.66–0.95, p = 0.01), 
all-cause mortality (HR 0.89, 95% CI 0.80–0.99, 
p = 0.047), and major bleeding (HR 0.69, 95% CI 0.60–
0.80, p < 0.001). The findings for the primary composite 
outcome was driven mainly by the large and significant 
reduction in hemorrhagic stroke rates among apixaban 
recipients (HR 0.51, 95% CI 0.35–0.75, p     < 0.001).  Liv-
er enzyme abnormalities were similar between the two 
treatment groups. 
This study was supported by Bristol-Myers Squibb 
and Pfizer. The industry sponsors participated in the de-
sign and conduct of the trial, as well as in the reporting 
of the results. Data analyses were performed at Bristol-
Myers Squibb and the Duke Clinical Research Institute.  
Implication and perspectives. We have entered a new 
and exciting era for anticoagulation. In the last several 
years, novel therapies have emerged as viable alterna-
tives to warfarin for the prevention of cardioembolism 
among  patients  with  atrial  fibrillation.  Although  war-
farin is highly effective at preventing stroke in patients 
with atrial fibrillation, only about half of patients who 
would  actually  benefit  from  therapy  actually  receive 
treatment.19 Barriers to successful use include its nar-
row therapeutic window, the associated hemorrhagic Clinical practice                                                                                                                          Leung & van Walraven
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risk, the need for frequent laboratory monitoring, and 
the plethora of drug-drug and drug-food interactions. In 
contrast, the new pharmacologic options are potentially 
safer and more convenient. Notably, the largely positive 
findings from the trials evaluating apixaban, dabigatran, 
and rivaroxaban (in comparison with warfarin) have all 
been driven by impressive reductions in hemorrhagic 
stroke.18,20,21 Somewhat surprisingly, only higher-dose 
dabigatran, when compared with warfarin, has been re-
ported to reduce the risk of ischemic stroke.21 Although 
all three drugs appear to have more favourable bleeding 
profiles in comparison with warfarin,18,20,21 antidotes are 
not yet available, which poses problems in the setting 
of life-threatening hemorrhages or emergency surger-
ies. Although the general conclusions reached in ARIS-
TOTLE are broadly similar to those of previous trials, 
this study was uniquely powered to detect a mortality 
benefit with apixaban,18 whereas previous studies evalu-
ating dabigatran and rivaroxaban have reported only 
non-significant  trends.20,21 Although the original task 
may have been to replace warfarin with a non-inferior 
alternative, ARISTOTLE boasts that apixaban may be 
even better.
Resolution of clinical vignette. The physician discusses 
with the patient the possibility of using a novel oral anti-
coagulant, rather than warfarin, for systemic anticoagu-
lation, particularly in light of the convenience, safety, 
and efficacy profiles of these new drugs.
 
5 
Simvastatin and ezetimibe in patients with 
chronic kidney disease
Clinical vignette. A 68-year-old man with chronic kidney 
disease and hypertension is referred for cardiovascular 
risk assessment. His current medications include acetyl-
salicylic acid 81 mg daily, ramipril 5 mg twice daily, and 
amlodipine 10 mg daily. Examination is unremarkable, 
with a blood pressure of 110/70 mmHg. Laboratory in-
vestigations reveal a stable creatinine of 180 μmol/L, 
LDL cholesterol of 2.97 mmol/L, and a urinary albumin-
to-creatinine ratio < 30 mg/g.
Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, 
et al. The effects of lowering LDL cholesterol with simvastatin plus 
ezetimibe in patients with chronic kidney disease (Study of Heart and 
Renal Protection): a randomised placebo-controlled trial. Lancet 2011 
25;377(9784):2181-92. Available from: www.sciencedirect.com/sci-
ence/article/pii/S0140673611607393 
 
Summary  of  findings.  The Study of Heart and Renal 
Protection (SHARP) was a double-blinded, randomized 
controlled trial designed to assess the safety and efficacy 
of reducing LDL cholesterol in 9270 patients with chron-
ic kidney disease.22 Patients were randomly assigned to 
receive simvastatin 20 mg daily plus ezetimibe 10 mg 
daily (4650 patients) vs double-placebo (4620 patients).   
Over the median follow-up of 4.9 years, the combination 
of simvastatin and ezetimibe resulted in an average LDL 
cholesterol reduction of 0.85 mmol/L and a 17% relative 
risk reduction in the primary outcome of major athero-
sclerotic events (11.3% simvastatin plus ezetimibe vs 
13.4% placebo; absolute risk reduction [ARR] 2.1%; rate 
ratio [RR] 0.83, 95% CI 0.74—0.94, p = 0.0021). Although 
there  were  significant  differences  in  non-hemorrhagic 
stroke (ARR 1.0%; RR 0.75, 95% CI 0.60–0.94, p = 0.01) 
and revascularization rates (ARR 1.5%; RR 0.79, 95% 
CI 0.68–0.93, p = 0.0036) in favour of simvastatin and 
ezetimibe, there was no difference in the rate of coronary 
events (p  =  0.37).  Moreover, there was no difference in 
mortality from any cause (p = 0.63). Subgroup analyses 
suggested that the impact of simvastatin and ezetimibe 
was similar between patients on dialysis compared with 
those who were not (p = 0.25 for heterogeneity). The use 
of simvastatin plus ezetimibe appeared safe with no ex-
cess risk of cancer, muscle pain, increases in creatinine 
kinase, hepatitis, or gallstones.
This study was supported by Merck/Schering-Plough 
Pharmaceuticals, the Australian National Health Med-
ical Research Council, the British Heart Foundation, 
and the UK Medical Research Council. The authors as-
sert that, although Merck/Schering-Plough Pharmaceut-
icals participated in the trial design and commented on 
study reports, none of the funding sources had a role in 
the conduct of the trial, analysis of data, or reporting of 
the results.
Implication  and  perspectives.  It has been suggested 
that, as renal function deteriorates, vascular stiffness 
and calcification become more important contributors 
to cardiovascular disease compared with atherosclero-
sis.23 As such, there has been uncertainty—and several 
“negative” trials—surrounding the benefit of LDL-lower-
ing therapy in the setting of renal impairment.24–26 Ad-
dressing this, the SHARP investigators provide evidence 
that the combination of simvastatin plus ezetimibe is 
safe and reduces the risk of major atherosclerotic events 
among patients with chronic kidney disease. The data 
suggest that for every 1 mmol/L reduction in LDL chol-
esterol there is an ARR of 2.1% for major atherosclerotic 
events (NNT 48) over 5 years, thus supporting the use Clinical practice                                                                                                                          Leung & van Walraven
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of LDL-lowering therapy in this high-risk population. 
The observation that no overall mortality benefit was ob-
served in this trial should not be inherently surprising, 
given that statins reduce atherosclerotic cardiac death 
but have little impact on other causes of death, even 
in the general population.27 A much larger trial would 
likely be needed to detect any benefit in vascular mor-
tality from LDL reduction, as coronary heart disease ac-
counted only for a minority (24%) of vascular deaths in 
SHARP. Nonetheless, this well-conducted study estab-
lishes the safety of simvastatin and ezetimibe therapy 
in this vulnerable population, and further demonstrates 
therapeutic efficacy.
Resolution of clinical vignette. This patient is started 
on simvastatin 20 mg daily for primary prevention. If 
needed, ezetimibe 10 mg daily will be added to target 
a 1 mmol/L reduction in LDL cholesterol. Beyond his 
lipid-lowering therapy, he continues to receive attentive 
blood pressure assessments for his overall cardiovascu-
lar health.
Conclusion
The medical community continues to be enriched by 
valuable research that enhances care, relieves suffering, 
and guides health policy. However, clinicians will con-
tinue to seek easily assessible and reliable synoptic re-
sources to keep up with rapidly expanding information.1–3 
Therefore, the annual review remains an irreplaceable 
tool to facilitate information delivery. Finally, although 
the articles that we have highlighted here are indisput-
ably important, we would be remiss not to emphasize 
that countless other high-quality studies could not be 
reviewed because because of constraints of space. 
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